Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 21.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,351 shares of the medical research company’s stock after selling 371 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Charles River Laboratories International were worth $249,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. increased its holdings in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the period. GeoWealth Management LLC raised its position in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new stake in Charles River Laboratories International in the 4th quarter valued at about $48,000. Finally, Tortoise Investment Management LLC boosted its stake in shares of Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after buying an additional 115 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

CRL has been the topic of a number of recent research reports. UBS Group restated a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their price objective for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Robert W. Baird dropped their target price on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Finally, JPMorgan Chase & Co. decreased their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $182.00.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster acquired 6,075 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This represents a 3.42 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $114.71 on Friday. The company’s 50 day simple moving average is $146.73 and its 200-day simple moving average is $171.12. The firm has a market cap of $5.63 billion, a PE ratio of 764.73, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period last year, the firm posted $2.46 EPS. Charles River Laboratories International’s revenue for the quarter was down 1.1% on a year-over-year basis. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).